Thelansis

Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook Thelansis’s “Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diffuse Intrinsic Pontine Glioma (DIPG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have...

Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook Thelansis’s “Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diffuse Intrinsic Pontine Glioma (DIPG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Diffuse Intrinsic Pontine Glioma (DIPG) Overview Diffuse intrinsic pontine glioma (DIPG) is an aggressive form of childhood cancer primarily found in the brainstem, with a remarkably low occurrence rate that predominantly affects pediatric patients. Approximately 10% of DIPG cases lack specific histological features such as mitotic figures and microvascular proliferation, aligning them w...

Diffuse intrinsic pontine glioma (DIPG) is a lethal malignant pediatric tumour that spreads throughout the pons. Pediatric gliomas with a K27M mutation in histone H3 with a diffuse growth pattern in a midline location are referred to as diffuse midline glioma, H3 K27M mutant; this designation is inclusive of DIPG cases bearing the K27M mutation. This devastating disease has a median age of 6-7 years at diagnosis and is rarely detected in adults. Given its eloquent location, current treatment options are limited, and the prognosis is dismal—with less than 10% of patients surviving beyond two years from the time of diagnosis. DIPGs account for 80% of all paediatric brain tumours in the brainstem. These tumours share histological characteristics with anaplastic astrocytomas (grade III) or glioblastomas (GBM) (grade IV. Brainstem gliomas affect approximately 350 to 450 children in the United States annually and are the major cause of death in children with brain tumours. The ...